I've been tracking a group of new announcements in recent weeks of drug developers pairing up with diagnostics companies to develop tests in conjunction with novel therapeutics. Signs are ripe that the joint development of therapeutics and diagnostics will grow increasingly important as researchers narrow their targets in a new generation of personalized meds. The same technology will have a big role to play in reducing the size of late-stage trials and hopefully shrinking costs while improving data. But revolutions in biotechnology always play out on an evolutionary timeline. Like everything else about biotechnology, early excitement is likely to give way to disappointment unless immediate results are seen. As an industry, we need to find a way to applaud progress without inciting over-expectations. - John Carroll